Skin antifungals

Fungi and dermatological sites

Dermatophytes and yeasts are terms associated with cutaneous fungal infections, not names for a single microorganism. Skin surfaces, folds, nails and the scalp represent different sites. A nail disorder is therefore not simply a skin infection described using another word. These distinctions help explain the variety of dosage forms and authorised indication information. A symptom name or redness alone cannot establish a fungal cause, and a product intended for skin care does not automatically become an antifungal medicine because of that destination.

Antifungal families and administration routes

The ATC index distinguishes dermatological antifungals from general systemic antimycotics and gynaecological preparations. Dermatology itself includes both local and systemic agents. Azole derivatives and allylamines illustrate different chemical families. A substance can also appear in more than one setting depending on its presentation. Cutaneous, nail or mucosal use should consequently not be inferred from the molecule name alone; route and the medicine's authorised indications provide the relevant context. A common family relationship does not establish identical sites of use for every preparation.

Creams, solutions and medicated nail lacquers

A cream is a semisolid formulation, a solution is liquid, and a medicated nail lacquer has a documented nail-related purpose. These are not equivalent packs of one uniform product. Substance, concentration and complete formulation provide useful pharmaceutical distinctions. Powders and foot hygiene products do not all become antifungal medicines simply because they are intended for feet. In professional practice, separating regulatory status, application site and dosage form helps distinguish wider product families from particular medicinal products without implying that one can replace another.

Frequently asked questions